【摘要】：絕經(jīng)后骨質(zhì)疏松癥(postmenopausal osteoporosis,PMOP)是指絕經(jīng)后婦女體內(nèi)雌激素水平下降,骨形成和骨吸收失耦連,導(dǎo)致以骨量減少和骨組織顯微結(jié)構(gòu)破壞為特征的一種全身代謝性骨病,是絕經(jīng)后婦女的常見病及多發(fā)病。隨著我國人口老齡化,絕經(jīng)后骨質(zhì)疏松癥以其高發(fā)病率、高致殘率逐漸成為嚴(yán)峻的公共衛(wèi)生及社會問題。臨床治療絕經(jīng)后骨質(zhì)疏松癥的藥物以西藥為主,中藥為輔,但西藥嚴(yán)重的毒副作用和中藥作用機(jī)制的不明確都制約著其進(jìn)一步的推廣。目前,隨著骨代謝機(jī)制的進(jìn)一步明確和相關(guān)診療技術(shù)的突破,臨床用藥有了新的進(jìn)展。本文以臨床藥物治療為出發(fā)點(diǎn),從西藥、中藥兩個方面入手,通過查閱國內(nèi)外近期相關(guān)文獻(xiàn),對西藥類(基礎(chǔ)藥物,抗骨吸收藥物、促進(jìn)骨形成藥物、雙重藥理作用藥物)和中藥類(單味中藥、中藥提取物、復(fù)方制劑)的臨床使用現(xiàn)狀進(jìn)行歸納總結(jié),同時提出筆者對絕經(jīng)后骨質(zhì)疏松癥藥物治療現(xiàn)狀的思考。
[Abstract]:Postmenopausal osteoporosis (postmenopausal osteoporosis,PMOP) is a systemic metabolic bone disease characterized by decreased estrogen levels, bone formation and bone resorption decoupling in postmenopausal women, characterized by reduced bone mass and destruction of bone microstructure. It is a common and frequent disease in postmenopausal women. With the aging of population, postmenopausal osteoporosis has become a serious public health and social problem due to its high morbidity and high disability rate. Western medicine is the main drug in the treatment of postmenopausal osteoporosis, while Chinese medicine is supplementary. However, the serious side effects of western medicine and the unclear mechanism of action of traditional Chinese medicine restrict its further promotion. At present, with the further clarification of bone metabolism mechanism and breakthrough of related diagnosis and treatment technology, clinical drug use has made new progress. Starting with clinical drug therapy, starting with western medicine and traditional Chinese medicine, and referring to the recent literature at home and abroad, the article discusses the western medicine (basic drugs, anti-bone absorption drugs, promoting bone formation drugs). The present situation of clinical use of traditional Chinese medicine (single Chinese medicine, extract of traditional Chinese medicine, compound preparation) was summarized, and the author's thoughts on drug treatment of postmenopausal osteoporosis were put forward.
【作者單位】： 福建中醫(yī)藥大學(xué);
【基金】：國家自然科學(xué)基金資助項(xiàng)目(81574003) 福建省科技廳引導(dǎo)性項(xiàng)目(2015Y0069) 陳可冀中西醫(yī)結(jié)合發(fā)展基金資助(CKJ201411)
【分類號】：R580
，

本文編號：2290705